Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy
about
Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategiesDiscovery and development of natural product oridonin-inspired anticancer agentsDirect Activation of Bax Protein for Cancer TherapyCurrent status and perspectives of patient-derived xenograft models in cancer research.Galectin-3 as a Potential Target to Prevent Cancer Metastasis.Echinacoside induces apoptotic cancer cell death by inhibiting the nucleotide pool sanitizing enzyme MTH1.Hesperidin from Citrus seed induces human hepatocellular carcinoma HepG2 cell apoptosis via both mitochondrial and death receptor pathwaysPatient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancerBH4 domain of Bcl-2 as a novel target for cancer therapyCopy-number variation of MCL1 predicts overall survival of non-small-cell lung cancer in a Southern Chinese population.Noninvasive bioluminescence imaging of the dynamics of sanguinarine induced apoptosis via activation of reactive oxygen species.BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth.How does metabolism affect cell death in cancer?2-aryl benzimidazole conjugate induced apoptosis in human breast cancer MCF-7 cells through caspase independent pathway.Non-canonical roles of Bcl-2 and Bcl-xL proteins: relevance of BH4 domain.Bcl-2 proteins and calcium signaling: complexity beneath the surface.Synergistic killing of human small cell lung cancer cells by the Bcl-2-inositol 1,4,5-trisphosphate receptor disruptor BIRD-2 and the BH3-mimetic ABT-263.Targeting cell death signalling in cancer: minimising 'Collateral damage'.Modulation of Ca2+ Signaling by Anti-apoptotic B-Cell Lymphoma 2 Proteins at the Endoplasmic Reticulum-Mitochondrial Interface.Cabazitaxel operates anti-metastatic and cytotoxic via apoptosis induction and stalls brain tumor angiogenesis.MicroRNA-9 promotes proliferation of leukemia cells in adult CD34-positive acute myeloid leukemia with normal karyotype by downregulation of Hes1.Silver nanoparticles enhance the apoptotic potential of gemcitabine in human ovarian cancer cells: combination therapy for effective cancer treatment.Targeting Bcl2 in cancer.Antagonizing Bcl-2's BH4 domain in cancer.B7-H3 combats apoptosis induced by chemotherapy by delivering signals to pancreatic cancer cells.Targeting Mcl-1 enhances DNA replication stress sensitivity to cancer therapy.TAT‑fused IP3R‑derived peptide enhances cisplatin sensitivity of ovarian cancer cells by increasing ER Ca2+ release.A double point mutation at residues Ile14 and Val15 of Bcl-2 uncovers a role for the BH4 domain in both protein stability and function.Reciprocal sensitivity of diffuse large B-cell lymphoma cells to Bcl-2 inhibitors BIRD-2 versus venetoclax.Modulation of Bax and mTOR for Cancer Therapeutics.HCRP1 is downregulated in non-small cell lung cancer and regulates proliferation, invasion, and drug resistance.Silencing of long non-coding RNA MIR22HG triggers cell survival/death signaling via oncogenes YBX1, MET, and p21 in lung cancer.
P2860
Q26750639-78D4BF87-E30F-482D-9656-7B7C4DD5FE05Q28387804-22775E2E-CC46-462E-893C-801CAE2BC6A7Q30353924-A7E1601D-2A0D-4D5E-8DC3-B08FAA395189Q33667686-2A78CA74-487C-4F94-BC65-96E0E92AFEFFQ36326176-983621E0-B109-479D-8644-3932766AD789Q36368301-D8D0568F-5EA1-43BA-BC9F-D9FA62C100A1Q36827731-C4339679-FB26-4B0B-B28F-B92C1424095FQ36866821-AE75DA0F-1477-4A86-8F6F-CE8CE6E93225Q36940766-1EDFCEA8-D659-48C7-9FB6-7ED07081A309Q36983665-09890B0C-EF5D-4D58-9A71-8806D5B29D1FQ37225547-F9DE0636-7C06-4F4B-BAE9-12B7BD38F61EQ37317385-2D97BBE0-2402-46F6-9B90-1CF8F7133AA6Q38615890-992BCCDA-C30D-4F9F-BD7A-FEDE8841C1CCQ38738909-3BC223FA-1846-4094-A0A6-19A84DF8F533Q38756877-9AD55F8F-80A2-4BCB-9623-4D0F505D9E79Q38773462-D33F323C-A0DA-4762-9BE9-0FF2F326F77CQ38807526-94BBD5CE-77DE-49C4-AAC5-5D66DCECC3D2Q38824157-0A41E83B-A172-416B-AD4D-49A3587A2685Q39313975-E415F79A-002C-460E-A8BD-3A2C553CB684Q39749702-5815021A-624C-406D-A596-8394751A5BB8Q40867295-0A05B760-AD52-4B99-A439-0BC0D6A7231FQ41382206-96597F76-679A-4ECB-B2F4-16EB70543B28Q43141056-99565137-1C94-4AFB-84B7-6BDF3A8A52B9Q43184271-2E457E83-4AB5-4087-8D47-D1F29B5214E6Q47138333-24EA572F-23E1-4573-9F67-DA1B25F1D9B4Q47308626-DDB1EA42-4444-48CC-9E76-D5E078415CC5Q47329282-BFE30402-565E-4EC5-8CDF-B7A6F8FB306AQ47409394-3855CDDE-EF11-4E79-B3F1-186561CC7ED8Q50017171-7A04DEB2-29D9-41F2-9F18-2110A81E2FD4Q50662513-0A8E46FA-50CC-4DA0-B47D-1AF0878F7F1DQ51395361-6791BB60-2A57-4189-BA0B-9BF6FF729488Q52579803-C0AB76F9-D7CF-4AEC-9ECC-07483C120F52
P2860
Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy
@ast
Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy
@en
Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy
@en-gb
Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy
@nl
type
label
Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy
@ast
Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy
@en
Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy
@en-gb
Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy
@nl
prefLabel
Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy
@ast
Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy
@en
Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy
@en-gb
Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy
@nl
P2093
P2860
P3181
P1433
P1476
Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy
@en
P2093
Bingshe Han
Chunyong Ding
Dong M Shin
Dongkyoo Park
Fadlo R Khuri
Gabriel L Sica
Guojing Zhang
Maohua Xie
P2860
P304
P3181
P356
10.1016/J.CCELL.2015.04.010
P407
P577
2015-06-08T00:00:00Z